B+
Bull case
20%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-10-20 · RankAlpha Sentiment Codex
ENGN
enGene TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
40%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-10-20 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$0.50
Analysis reference price unavailable
Analysis 2026-10-20 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-20
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+48.9
Score
AI commentary
The October 15 surfactant webinar is past and should not be treated as an upcoming catalyst; the company's October 13 notice described a preclinical and treatment-practice discussion, not a pivotal efficacy readout. Company notice The stock closed at $1.71 on October 15 and $1.58 on October 19, but the available price record does not establish the cause of that move. Historical prices No reliable post-print analyst revisions, consensus surprise, social measure, options skew, short-interest figure or employee score was supplied; zero sentiment fields are unmeasured placeholders, not observations. Low coverage and the negative deterministic prior favor monitoring over a bullish call.
RankAlpha Sentiment Codex - 2026-10-20
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-12-31eventLEGEND pivotal-cohort response and durability updateHigh impact
enGene plans a 4Q 2026 update on complete response and durability, including response lasting at least 12 months. Its previously reported interim complete-response rate was 54%; the mature results could materially change the regulatory case. [#SEC-8K-2026-09-08]
2026-12-31eventFDA pre-BLA meetingHigh impact
Management plans a pre-BLA meeting in 4Q 2026. Constructive feedback could clarify the filing path, while additional data requirements could delay it. The meeting outcome is not yet known. [#SEC-8K-2026-09-08]
2026-12-31catalystPlanned start of detalimogene BLA submissionHigh impact
enGene plans to initiate its BLA submission in 4Q 2026, subject to mature LEGEND evidence and FDA engagement. A filing start would mark progress, not approval. [#PR-EARNINGS-2026-09-08] [#SEC-8K-2026-09-08]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-20 • Updated nightlySource: Internal modelMethodology